全文获取类型
收费全文 | 7422篇 |
免费 | 573篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 152篇 |
儿科学 | 108篇 |
妇产科学 | 176篇 |
基础医学 | 946篇 |
口腔科学 | 222篇 |
临床医学 | 788篇 |
内科学 | 1603篇 |
皮肤病学 | 145篇 |
神经病学 | 639篇 |
特种医学 | 678篇 |
外科学 | 1366篇 |
综合类 | 35篇 |
预防医学 | 231篇 |
眼科学 | 156篇 |
药学 | 323篇 |
中国医学 | 2篇 |
肿瘤学 | 458篇 |
出版年
2024年 | 12篇 |
2023年 | 105篇 |
2022年 | 189篇 |
2021年 | 334篇 |
2020年 | 197篇 |
2019年 | 292篇 |
2018年 | 319篇 |
2017年 | 235篇 |
2016年 | 259篇 |
2015年 | 312篇 |
2014年 | 405篇 |
2013年 | 403篇 |
2012年 | 615篇 |
2011年 | 609篇 |
2010年 | 368篇 |
2009年 | 361篇 |
2008年 | 432篇 |
2007年 | 424篇 |
2006年 | 335篇 |
2005年 | 310篇 |
2004年 | 248篇 |
2003年 | 241篇 |
2002年 | 171篇 |
2001年 | 88篇 |
2000年 | 66篇 |
1999年 | 83篇 |
1998年 | 27篇 |
1997年 | 36篇 |
1996年 | 23篇 |
1995年 | 11篇 |
1994年 | 11篇 |
1993年 | 12篇 |
1992年 | 28篇 |
1991年 | 25篇 |
1990年 | 18篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 25篇 |
1986年 | 26篇 |
1985年 | 21篇 |
1984年 | 14篇 |
1983年 | 12篇 |
1982年 | 11篇 |
1981年 | 12篇 |
1979年 | 23篇 |
1975年 | 12篇 |
1932年 | 13篇 |
1931年 | 8篇 |
1924年 | 12篇 |
1922年 | 8篇 |
排序方式: 共有8028条查询结果,搜索用时 0 毫秒
61.
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. 总被引:14,自引:0,他引:14
Philipp Str?bel Andrea Bauer Bernhard Puppe Til Kraushaar Axel Krein Klaus Toyka Ralf Gold Michael Semik Reinhard Kiefer Wilfred Nix Berthold Schalke Hans Konrad Müller-Hermelink Alexander Marx 《Journal of clinical oncology》2004,22(8):1501-1509
PURPOSE: Thymic epithelial tumors (TET) are rare epithelial neoplasms of the thymus with considerable histologic heterogeneity. This retrospective study focused on the correlation of WHO-defined TET histotypes with survival and tumor recurrence in a large cohort of patients receiving different modes of treatment. PATIENTS AND METHODS: Two hundred twenty-eight patients were followed for up to 21 years (median, 60 months; range, 1 to 252 months) after primary surgery. Forty-two patients received adjuvant radiotherapy (mean dose, 53 Gy), and 33 patients received adjuvant chemotherapy. RESULTS: Seventy-six (88%) of 86 patients with WHO type A, AB, and B1 thymomas were treated by surgery alone, with three tumor relapses after 3 to 10 years (median, 3.4 years). Twelve of 67 patients with WHO type B2 and B3 thymomas in Masaoka stages I and II were treated by adjuvant radiotherapy without evidence of tumor recurrence after 1 to 12 years (median, 4 years). Among 75 patients with B2 and B3 thymomas with incomplete resection or a tumor stage III or higher, the recurrence rate was 34% (n = 23) after 0.5 to 17 years (median, 5 years) in patients receiving adjuvant radiochemotherapy, compared to 78% (seven of nine patients) in patients without adjuvant radiochemotherapy. Incomplete tumor resection was associated with a high recurrence rate (65%) and a poor prognosis (P <.01). CONCLUSION: The long-term outcome of TET patients is related to tumor stage, WHO histotype, completeness of surgical removal, and type of treatment. Prospective trials are warranted to formally address the efficacy of adjuvant therapy in the treatment of localized and advanced malignant TETs. 相似文献
62.
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. 总被引:5,自引:0,他引:5
Hans Herbert Steiner Matteo Mario Bonsanto Philipp Beckhove Michael Brysch Karsten Geletneky Rezvan Ahmadi Rebecca Schuele-Freyer Paul Kremer Golamreza Ranaie Dejana Matejic Harald Bauer Marika Kiessling Stefan Kunze Volker Schirrmacher Christel Herold-Mende 《Journal of clinical oncology》2004,22(21):4272-4281
PURPOSE: Prognosis of patients with glioblastoma is poor. Therefore, in glioblastoma patients, we analyzed whether antitumor vaccination with a virus-modified autologous tumor cell vaccine is feasible and safe. Also, we determined the influence on progression-free survival and overall survival and on vaccination-induced antitumor reactivity. PATIENTS AND METHODS: In a nonrandomized study, 23 patients were vaccinated and compared with nonvaccinated controls (n = 87). Vaccine was prepared from patient's tumor cell cultures by infection of the cells with Newcastle Disease Virus, followed by gamma-irradiation, and applied up to eight times. Antitumor immune reactivity was determined in skin, blood, and relapsed tumor by delayed-type hypersensitivity skin reaction, ELISPOT assay, and immunohistochemistry, respectively. RESULTS: Establishment of tumor cell cultures was successful in approximately 90% of patients. After vaccination, we observed no severe side effects. The median progression-free survival of vaccinated patients was 40 weeks (v 26 weeks in controls; log-rank test, P = .024), and the median overall survival of vaccinated patients was 100 weeks (v 49 weeks in controls; log-rank test, P < .001). Forty-five percent of the controls survived 1 year, 11% survived 2 years, and there were no long-term survivors (> or = 3 years). Ninety-one percent of vaccinated patients survived 1 year, 39% survived 2 years, and 4% were long-term survivors. In the vaccinated group, immune monitoring revealed significant increases of delayed-type hypersensitivity reactivity, numbers of tumor-reactive memory T cells, and numbers of CD8(+) tumor-infiltrating T-lymphocytes in secondary tumors. CONCLUSION: Postoperative vaccination with virus-modified autologous tumor cells seems to be feasible and safe and to improve the prognosis of patients with glioblastomas. This could be substantiated by the observed antitumor immune response. 相似文献
63.
Herget-Rosenthal S Trabold S Pietruck F Holtmann M Philipp T Kribben A 《American journal of nephrology》2000,20(2):97-102
Serum cystatin C, a cysteine proteinase inhibitor, has been proposed as a marker of glomerular filtration rate (GFR). Serum cystatin C, serum creatinine and creatinine clearance were measured in 226 patients with various nephropathies, covering the entire range of renal function, to evaluate the efficacy of cystatin C as a screening test to detect reduced creatinine clearance in comparison to creatinine. Subgroups of 53 patients with glomerular and 26 patients with tubular impairment were compared to assess whether cystatin C performed differently in either glomerular or tubular impairment. Cystatin C detected reduced creatinine clearance with higher sensitivity (97 vs. 83%), and higher negative predictive value (96 vs. 87%) compared to creatinine. In parallel, 95% sensitivity of cystatin C as derived from receiver-operating characteristic plot was significantly higher (p < 0.05). In the subgroups with glomerular or tubular impairment, cystatin C and creatinine did not significantly differ with regard to efficacy. Serum cystatin C is as efficacious as serum creatinine to detect reduced GFR as measured by creatinine clearance. The efficacy of cystatin C as a screening test may even be superior compared to creatinine. In addition, the efficacy of cystatin C is independent of either glomerular or tubular impairment. 相似文献
64.
65.
66.
67.
Mattis Bertlich Saskia Freytag Tobias Dombrowski Philipp Jurmeister Jennifer Lee Spiegel Ines Bertlich Friedrich Ihler Bernhard G. Weiss Frank Haubner Moritz Grger 《Medicine》2022,101(45)
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS. 相似文献
68.
Marina Aznaourova Nils Schmerer Harshavardhan Janga Zhenhua Zhang Kim Pauck Judith Bushe Sarah M. Volkers Daniel Wendisch Philipp Georg Evgenia Ntini Michelle Aillaud Margrit Gündisch Elisabeth Mack Chrysanthi Skevaki Christian Keller Christian Bauer Wilhelm Bertrams Annalisa Marsico Andrea Nist Thorsten Stiewe Achim D. Gruber Clemens Ruppert Yang Li Holger Garn Leif E. Sander Bernd Schmeck Leon N. Schulte 《Proceedings of the National Academy of Sciences of the United States of America》2022,119(36)
69.
Ueli Bütikofer Ren Badertscher Carola Blaser-Freiburghaus Pascal Fuchsmann Mireille Tena Stern Philipp A. Kuert Grgory Pimentel Kathryn Jane Burton-Pimentel Nathalie Vionnet Guy Vergres 《Nutrients》2022,14(22)
The identification of molecular biomarkers that can be used to quantitatively link dietary intake to phenotypic traits in humans is a key theme in modern nutritional research. Although dairy products (with and without fermentation) represent a major food group, the identification of markers of their intake lags behind that of other food groups. Here, we report the results from an analysis of the metabolites in postprandial serum and urine samples from a randomized crossover study with 14 healthy men who ingested acidified milk, yogurt, and a non-dairy meal. Our study confirms the potential of lactose and its metabolites as markers of lactose-containing dairy foods and the dependence of their combined profiles on the fermentation status of the consumed products. Furthermore, indole-3-lactic acid and 3-phenyllactic acid are two products of fermentation whose postprandial behaviour strongly discriminates yogurt from milk intake. Our study also provides evidence of the ability of milk fermentation to increase the acute delivery of free amino acids to humans. Notably, 3,5-dimethyloctan-2-one also proves to be a specific marker for milk and yogurt consumption, as well as for cheese consumption (previously published data). These molecules deserve future characterisation in human interventional and observational studies. 相似文献
70.